AsymBio is a tech-influenced Contract Development and Manufacturing Organisation (CDMO) and a division of Asymchem Group. This CDMO responsible company was found to offer a well unified services for novel drug conjugates and biologics. The companies hands on expertise and confidence lies in the development of mRNA, plasmid, ADC and antibodies with its trusted solutions and proven marketing, manufacturing and R&D operations.
AsymBio's new integrated technology platforms are a bridge to the full biopharmaceutical development life span. With the company’s full-fledged service potential, the company offers systematic, unified operations for client programs covering its end to end responsibility from early development to marketing and manufacturing.
As learned, AsymBio is a tech-inspired CDMO with its all concentration on innovation and services. The company runs these services on various major platforms, like the AmigoCHO™ Cell Line Development Platform. This platform contributes to the establishment of quality, stable and stringent clones, which also involves extension, balancing analysis, clone selection and cell pool development.
Another, Downstream Process Development Platform is a relief to the development timelines as it's engineered to consume less time, alongside it enhances yield, mitigates impurities and contributes to the purified product. This platform plays a major role in filtration process development, process specification, process development, tech transfer and performance scaling.
Whereas, the company’s upstream process development platform encompasses refining process, specification and promising workflows from the precise preclinical material preparation. Following this IND/BLA allow process development and cuts the assignment timeline by around 9 weeks. Whereas, the IMPACT Drug Product Development Platform serves phase responsible drug product development, molecule and indication services.
The effective and supportive dosage forms are chilled liquid presentations, liquid, and lyophilised with an accent on process and formulation solutions for capable and crucial biologics. The Comprehensive Analytical Platform holds a potential value in addressing and performing the intensified product specification and analytical method development.
It almost encompasses and eases the critical quality attributes (CQAs) throughout each of the product’s lifespan levels and constitutes Bioassay Platform, Mass Spectrometry Platform and Physicochemical Platform.
With all these robust platforms, the new integrated technology platform is a powerful feather in the company’s service pipeline, with more strength for future endeavours. Moreover, AsymBio will be spending on technology establishments and R&D, like always, with an eye on data-supported manufacturing processes and modern technology platforms
Holding M.Pharm in Pharmaceutical Chemistry, Chandni crafts cutting-edge, research-driven healthcare news for Towards Healthcare, combining scientific depth with innovative storytelling to simplify complex topics for global readers.
